Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
By Shibo Jiang, C. Hillyer, L. Du. Trends in immunology, 2020
727 citations recorded by the source corpus.
Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.
Subfields: Infectious Diseases, Modeling and Simulation
View Paper: https://www.semanticscholar.org/paper/1c707a71a8193087aaedb6ad41e83ebfe388cf5e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response (2020, neutral): “Structurally, SARS-CoV-2 has four main structural proteins including spike (S) glycoprotein, small envelope (E) glycoprotein, membrane (M) glycoprotein, and nucleocapsid (N) protein, and also several accessory proteins [9].”
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia (2020, background): “11,12 When developing a vaccine (particularly during a pandemic), it is important to consider that a protective response must develop in a short time (eg, up to 1 month).”
- Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications (2020, background): “Furthermore, neutralizing antibodies can control SARS-CoV-2 infection in vitro and in vivo (4, 28, 29).”